Fierce Generic Competition Leads Astellas Into Tier-Based Pricing For Prograf In India
This article was originally published in PharmAsia News
Executive Summary
MUMBAI - Seventeen years after Prograf (tacrolimus) was first introduced into the market, Japan's second largest drug maker, Astellas Pharma, is still counting heavily on its blockbuster transplant drug to push future growth
You may also be interested in...
Indian Companies Are Becoming More Creative, Says Astellas India Managing Director Teruo Yasufuku: An Interview With PharmAsia News
Teruo Yasufuku, managing director for Astellas Pharma India, is soft-spoken and carefully measures every answer that he shares with the media. But the law graduate who started his career as a medical representative with Fujisawa in 1983 has been recognized for his leadership skills and the enthusiasm to be the best in the business. Terry, as he is called by his Indian industry contemporaries, can tirelessly talk about Prograf (tacrolimus) - Astellas' flagship transplant brand that notches worldwide sales upwards of $2 billion many years after it has been copied by generic companies. Yasufuku, along with his marketing director Himanshu Dave, proudly point at the back of their business cards, which say 'I Pledge To Donate - kidney, liver, heart, lung, pancreas, corneas.' This, Yasufuku asserts, is Astellas' unflinching commitment to the transplant segment. And, although it is a late entrant and faces intense generic competition, Prograf has a long roadmap laid out for growth in India. Yasufuku shares his wide angle on Astellas' India strategy with PharmAsia News India bureau.
Indian Companies Are Becoming More Creative, Says Astellas India Managing Director Teruo Yasufuku: An Interview With PharmAsia News
Teruo Yasufuku, managing director for Astellas Pharma India, is soft-spoken and carefully measures every answer that he shares with the media. But the law graduate who started his career as a medical representative with Fujisawa in 1983 has been recognized for his leadership skills and the enthusiasm to be the best in the business. Terry, as he is called by his Indian industry contemporaries, can tirelessly talk about Prograf (tacrolimus) - Astellas' flagship transplant brand that notches worldwide sales upwards of $2 billion many years after it has been copied by generic companies. Yasufuku, along with his marketing director Himanshu Dave, proudly point at the back of their business cards, which say 'I Pledge To Donate - kidney, liver, heart, lung, pancreas, corneas.' This, Yasufuku asserts, is Astellas' unflinching commitment to the transplant segment. And, although it is a late entrant and faces intense generic competition, Prograf has a long roadmap laid out for growth in India. Yasufuku shares his wide angle on Astellas' India strategy with PharmAsia News India bureau.
Astellas Sees Turnaround With Urology, Transplantation And Oncology Products
Astellas has rolled out a five-year management plan to bounce back from patent expiries and declining sales; and fresh off a long-fought bid for OSI Pharmaceuticals, the company expects oncology to bolster growth driven by its core therapeutic competencies of urology and transplantation